Introduction {#Sec1}
============

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fractures \[[@CR1]\]. The high societal and personal costs of osteoporosis pose challenges to public health and physicians \[[@CR2]\]. Adequate dietary intakes of key bone nutrients such as calcium, vitamin D, and proteins contribute to bone health and reduce the risk of fracture later in life \[[@CR2]--[@CR4]\]. A recent European consensus recommends adequate vitamin D intake of 800 IU/day to maintain serum 25-OH hydroxyvitamin D levels \>50 nmol/L as well as calcium intake of 1000 mg/day \[[@CR3], [@CR5]\]. There is a high prevalence of vitamin D insufficiencies in the elderly and dietary calcium is low in many postmenopausal osteoporotic women \[[@CR2], [@CR5]--[@CR8]\]. Dietary sources of nutrients are the preferred option and pharmacological supplementation should only be targeted to those individuals who do not get sufficient calcium from their diet and who are at increased risk for osteoporosis \[[@CR2]\]. As calcium is mainly provided in dairies, calcium and vitamin D-fortified dairy products (e.g., yogurt, milk,...) providing at least 40 % of the recommended nutrient intake (RNI) of calcium (400 mg) and 200 IU of vitamin D per portion are considered valuable options that are likely to improve long-term adherence \[[@CR2]\]. Indeed, dairy food has been shown to provide calcium with good compliance compared to pharmacological supplements \[[@CR9]\]. This phenomenon might be emphasized by recent publications suggesting that pharmacological calcium supplements might be associated with adverse health events of which dairy products intake appears to be deprived \[[@CR10]\]. Amazingly, though this recommendation is claimed to be justified both in terms in efficacy and cost-effectiveness, few studies targeted the cost-effectiveness of calcium and vitamin D, and none, so far, assessed the economic value of fortified dairy products given to women at increased risk of fractures \[[@CR11], [@CR12]\]. Whereas low intake in calcium and vitamin D seems ubiquitous in most European countries \[[@CR2], [@CR6]--[@CR8]\], there are significant variations in the amount of these nutrients that postmenopausal women receive, hence making the case for a personalized supplementation, tailored on their real needs rather than systematically offering to all subjects the "standard" dose of 1 g of calcium and 800 IU of vitamin D per day. Therefore, the objectives of this study was therefore to assess the cost-effectiveness of the administration of one to three portions per day of a vitamin D-fortified yogurt given to elderly women with and without an increased risk of osteoporotic fracture.

Material and methods {#Sec2}
====================

Due to the previously described wide variation in calcium and vitamin D intake in women with and without an increased risk of osteoporosis \[[@CR2], [@CR6], [@CR8]\], we considered three scenarios, i.e., daily administration of one, two, or three portions of a yogurt fortified with vitamin D (each portion providing 400 mg of calcium and 200 IU of vitamin D) to reach the recommended daily intake of 1000 mg of calcium and 800 IU of vitamin D. The target population focused on women aged 65, 70, or 80 years, without increased risk of osteoporosis, or with low bone mineral density (BMD), defined as a T-score \< −2.5 at the spine and/or at the femoral neck or with a prevalent vertebral fracture (PVF).

We adapted an extensively published and validated cost-effectiveness model of osteoporosis management \[[@CR11], [@CR13]\]. The model is a microsimulation Markov model designed with TreeAge pro (TreeAge Pro Inc, Williamston, USA). The occurrence of fractures at individual ages is modeled through a health-state transition process (Markov model). Individuals begin one at a time in the non-fracture state and progress every 6 months (cycle length) according to age-specific fracture risk through the non-fracture state, hip fracture state, vertebral fracture state, wrist fracture state, or other fracture state. Similarly, individuals with a PVF begin one at a time in this state and progress also every 6 months to other fracture states according to age-specific fracture risk adjusted by the presence of this prior vertebral fracture. Microsimulation modeling is a way to integrate memory by taking into account the full history of the patient. For instance, the occurrence of fractures as time goes by is taken into account by tracker variables to adjust the future risks of fractures \[[@CR13]\]. The model has a lifetime horizon for each simulated patient. All patients can die from background mortality from any health state (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Model structure. Transition to death and from post-fracture (Fx) states to any fracture states. Death and no-fracture states were excluded from the diagram for simplicity. *CV* clinical vertebral fractures (from 9)

The risk of hip fracture was derived from the Belgian national database of hospital bills \[[@CR14]\]. Since the incidence of non-hip fracture was not known, we applied the age-specific ratio of index fracture to hip fracture in Belgium as found in Sweden \[[@CR15]\]. These risks of fractures in the general Belgian population were further adjusted for women with BMD T-score \< −2.5 and women with a PVF using a method described elsewhere \[[@CR16]\].

We assumed that individuals who had a previous fracture were at increased risk of a subsequent fracture at the same location. These increased relative risks of fracture were 2.3, 4.4, 3.3, and 1.9 for hip, vertebral, wrist, and others fractures, respectively \[[@CR13], [@CR17], [@CR18]\]. An increased risk of subsequent fractures at different sites from that of prior fractures was not modeled in the absence of supporting data except for a subsequent hip fracture following a vertebral fracture with an increased risk of 2.3 \[[@CR13]\].

The age-specific mortality rates were taken from official Belgian demographic statistics for the year 2012 (Pubic Federal Department of Economics, Brussels, 2015). We assumed that hip fracture increased death probabilities by 1.53 in the first 6 months following the fracture, by 1.75 in the 6--12 months following the fracture, and by 1.78 in subsequent year, as evidenced in a meta-analysis \[[@CR19]\]. The same excess mortality was assumed for vertebral fracture but not for wrist and others fractures.

Utility data of the general population and relative fracture disutility were taken from a published systematic review \[[@CR20]\]. When a second fracture occurred at the same site, the disutility applied to the first fracture was reduced by 50 % \[[@CR13], [@CR21]\].

Cat/Vit D supplementation effectiveness in the reduction of fracture incidence was taken from a recent study \[[@CR11]\] that reviewed and synthesized meta-analyses previously published on the subject. Ca/Vit D supplementation has been shown to reduce the risk of hip fracture by 18 % (RR = 0.82, 95 % CI 7.1--0.94; meta-analysis of 6 trials including 45,509 patients) \[[@CR22]\]. The risk of vertebral fracture by 13 % (RR = 0.87, 95 % Cl 0.75--1.01; meta-analysis including 45,164 patients) \[[@CR23]\] and the risk of non-hip non-vertebral fracture by 20 % (RR = 0.80, 95 % Cl 0.72--0.89; meta-analysis of 9 trials including 32,285 patients) \[[@CR24]\].

Patients were assumed to follow Ca/Vit D supplementation for 3 years. The protective effect of Ca/Vit D supplementation on fracture risk was then assumed to decline linearly for a period equal to the supplementation duration (i.e., 3 years). This assumption is aligned with previous cost-effectiveness analyses of osteoporosis treatment \[[@CR1], [@CR11], [@CR25]\].

The perspective for the cost calculation was that of the Belgian Health care payers (government and patients) as recommended in the Belgian pharmacoeconomics guideline \[[@CR26]\]. Only direct medical costs were taken into account. The hospitalization cost of hip fracture was retrieved from the Belgian national database of hospital bills for the year 2007. Extra costs in the year following a hip fracture were derived from a prospective study of 159 women \[[@CR27]\]. The costs of non-hip fractures were estimated relative to hip fracture \[[@CR28]\]. We assumed that non-hip fractures were not associated with long-term costs.

In the absence of official pricing data, as opposed to pharmaceuticals for instance, the price of dietary Ca/Vit D supplementation products was derived from the observed market prices of a yogurt containing 400 mg of Ca and 200 IU of Vit D per unit. The average price per pack of 4 U was 1.37 €, i.e., 0.34 € per unit.

We included the cost of one general practitioner visit (23 €) per year of supplementation and the cost of one bone densitometry at years 1 and 3 (59 € = 36 € the cost of bone densitometry + 23 € the cost of one additional general practitioner visit).

All costs were expressed in 2014 euros using the official Belgian health price index (Public Federal Department of Economics, Brussels, 2015).

Three supplementation scenarios were considered to reflect the Ca/Vit D needs of the female population with osteoporosis or with PVF, taking into account the well-known variations in dietary habits and a possible pharmacological supplementation in Ca/Vit D, given above or in combination with anti-osteoporosis medications: one enriched yogurt per day, i.e., 400 mg of Ca + 200 IU of Vit D (scenario 1 U), two enriched yogurt units per day, i.e., 800 mg of Ca + 400 IU of Vit D (scenario 2 U), or three enriched yogurt units per day, i.e., 1,200 mg of ca + 600 IU of Vit D (scenario 3 U). With a unit price of 0.34 € per yogurt, the annual costs were 125, 250, and 375 € for the 1 U, 2 U, and 3 U dietary Ca/Vit D supplementation scenarios, respectively.

Average costs and quality-adjusted life-years (QALYs) were then computed and compared through an incremental cost-effectiveness ratio (ICER). The incremental cost-effectiveness ratio (ICER) is calculated as follows:$$\documentclass[12pt]{minimal}
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We programmed and ran 27 microsimulations: 3 age groups (65 years, 70 years, and 80 years), 3 baseline risks (women without low BMD or a PVF, women with a BMD T-score \< −2.5, and women with a PVF), and 3 supplementation scenarios (1 U, 2 U, or 3 U of Ca/Vit D diary supplementations per day). Each microsimulation was run 10 times with 200,000 patients to enable variability analyses. The average ICERs with its 95 % confidence intervals were evaluated for each of the 27 microsimulations QALYs and costs were discounted at 1.5 and 3 % respectively.

Results {#Sec3}
=======

The incremental cost-effectiveness ratios of the daily intake of 1, 2, or 3 portions of a vitamin D-fortified yogurt to women aged 65, 70, or 80 years, with no increased risk of osteoporosis (general population), low BMD, and PVF are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"} and in Fig. [2](#Fig2){ref-type="fig"}. Taking an upper limit of 45,000 €/QALY as a threshold for cost-efficiency \[[@CR26]\], one daily portion of yogurt is cost-effective in the general population above the age of 70 years and in all age groups in women with low BMD or PVF. The daily intake of two portions of yogurt is cost-effective above 80 years in the general population and above 70 years in the two groups of women at increased risk of fractures. However, an intake of three yogurts per day is only cost-effective above 80 years old in all three groups of women.Table 1Costs, QALYs, and ICER for a supplementation with one portion per day (125 Euros/year)1 Unit/day (€125/year)Ca/Vit D supplementationNo supplementationIncrementalICER95 % CICostQALYsCostQALYsCostQALYsLowHighWomen without low BMD or prevalent vertebral fracture 65 years€ 688212.793€ 646112.788€ 4210.004€ 94,304€ 18,369€ 170,239 70 years€ 755610.183€ 722210.173€ 3330.010€ 34,513€ 16,406€ 52,620 80 years€ 76465.622€ 77015.605−€ 550.017−€ 3290−€ 5036−€ 1544Women with low BMD 65 years€ 10,44712.655€ 10,13712.643€ 3100.012€ 26,596€ 8465€ 44,726 70 years€ 10,82310.074€ 10,60710.060€ 2170.014€ 15,183€ 10,448€ 19,918 80 years€ 94645.571€ 96855.553−€ 2210.018−€ 12,237−€ 15,405−€ 9069Women with prevalent vertebral fracture 65 years€ 955412.528€ 919512.513€ 3590.015€ 24,345€ 14,736€ 33,954 70 years€ 10,4529.934€ 10,1749.914€ 2790.019€ 14,328€ 11,841€ 16,814 80 years€ 10,3605.453€ 10,6145.426−€ 2550.027−€ 9364−€ 11,793−€ 6934Table 2Costs, QALYs, and ICER for a supplementation with two portions per day (250 Euros/year)2 Units/day (€250/year)Ca/Vit D supplementationNo supplementationIncrementalICER (€)95 % CICost (€)QALYsCost (€)QALYsCost (€)QALYsLow (€)High (€)Women without low BMD or prevalent vertebral fracture 65 years722812.796643012.7897980.006123,12258,426187,819 70 years790910.181720110.1707090.01162,97538,00087,951 80 years80055.62076985.6013070.02015,57613,58617,566Women with low BMD 65 years10,76312.65310,10512.6416580.01256,49843,65569,340 70 years11,16310.07510,63210.0595310.01632,46722,29242,642 80 years98265.57696735.5541530.022686860767660Women with prevalent vertebral fracture 65 years994212.533919212.5187500.01648,01840,40255,634 70 years10,8219.93910,2089.9206130.01932,68522,29242,312 80 years10,6985.45110,6115.425880.026339027484032Table 3Costs, QALYs, and ICER for a supplementation with three portions per day (375 Euros/year)3 Units/day (€375/year)Ca/Vit D supplementationNo supplementationIncrementalICER (€)95 % CICost (€)QALYsCost (€)QALYsCost (€)QALYsLow (€)High (€)Women without low BMD or prevalent vertebral fracture 65 years759212.796641812.78811740.009136,24416,367256,121 70 years827210.187722510.17710470.010104,52362,106146,941 80 years83035.61877285.6025750.01537,11431,26442,964Women with low BMD 65 years11,10512.65610,09312.6411,0120.01471,05853,69488,422 70 years11,50510.07410,60810.0578970.01851,00245,73856,266 80 years10,1325.57097125.5524200.01823,14720,59825,695Women with prevalent vertebral fracture 65 years10,29012.531920712.51910830.01289,30379,78098,826 70 years11,1179.93410,1689.9189480.01658,00147,83768,165 80 years11,0395.45110,6335.4234070.02814,60213,50215,702Fig. 2**a** Incremental cost-effectiveness ratio of a supplementation with a dairy product fortified with vitamin D (400 mg calcium/200 IU vitamin D) as a function of age and cost of the dairy product (one daily portion: 125 €, two daily portions: 250 €, three daily portions: 375 €) in women without low bone mineral density or prevalent vertebral fractures. **b** Incremental cost-effectiveness ratio of a supplementation with a dairy product fortified with vitamin D (400 mg calcium/200 IU vitamin D) as a function of age and cost of the dairy product (one daily portion: 125 €, two daily portions: 250 €, three daily portions: 375 €) in women with low bone mineral density. **c** Incremental cost-effectiveness ratio of a supplementation with a dairy product fortified with vitamin D (400 mg calcium/200 IU vitamin D) as a function of age and cost of the dairy product (one daily portion: 125 €, two daily portions: 250 €, three daily portions: 375 €) in women with prevalent vertebral fractures

Discussion {#Sec4}
==========

This study is the first attempt to assess the cost-effectiveness of the daily intake of various amounts of a dairy product supplemented with vitamin D in women, at ages from 65 to 80 years and with or without prevalent osteoporosis. We selected a currently marketed yogurt which, as recommended by a recent published consensus guidance document for the management of osteoporosis \[[@CR2]\] provides, in each portion, 40 % of the RNI of calcium (400 mg) and 200 IU of vitamin D. Our results suggest that such a dietary supplementation in bone-friendly nutrients is cost-effective at ages varying from 65 to 80 years, depending on the prevalence of osteoporosis and on the number of portions required to reach the RNI. Low calcium intake in elderly subjects was repeatedly described, in the general population \[[@CR2], [@CR29]\] and in osteoporotic subjects \[[@CR2], [@CR8]\]. A recent survey of calcium intake from calcium-dense dairy products in fracture patients reported a wide distribution of daily calcium intake in these patients with more than 60 % of the subjects remaining below the RNI of 1 g/day \[[@CR30]\]. This is in accordance with one of our previous studies, conducted in patients with established osteoporosis, issued from nine European countries and showing that, while close to 40 % of the population took pharmacological calcium supplements, only a small subset of the patients had sufficient calcium intake \[[@CR8]\]. In most studies assessing questionnaires evaluating calcium intakes, the standard deviation amounts up to 50 % of the mean recorded value confirming large discrepancies between subjects and the need for a tailored supplementation based on the pre-existing calcium intake \[[@CR31]\]. Similarly, vitamin D inadequacy is well documented in normal and osteoporotic subjects \[[@CR5]--[@CR7], [@CR32]\] and the distribution of serum 25-hydroxyvitamin D concentrations, the principal index of vitamin D status \[[@CR3], [@CR5], [@CR6]\], shows a wide scatter in the degree of deficiency and in the subsequent need for supplementation. Our study is the first to consider a personalized approach for calcium and vitamin D supplementation, tailoring the administration of these supplements based on the amounts of calcium and vitamin D that are already spontaneously received by the patients.

We recently reported that a pharmacological supplementation of vitamin D and calcium is cost-effective for women and men aged 60 years with osteoporosis \[[@CR11]\]. This finding justifies the recommendation of the ESCEO working group to supplement all patients aged over 65 years with increased risk of fractures with calcium and vitamin D \[[@CR2], [@CR3]\]. This European consensus, however, recommends that dietary sources of nutrients are the preferred option for the supplementation of elderly subjects and that pharmacological supplementation should only be targeted to those individuals who do not get sufficient calcium from their diet \[[@CR2]\]. Amazingly, this recommendation was never, before the present trial, justified in terms of cost-effectiveness. Our study is the first economic analysis that estimates the cost-effectiveness of calcium and vitamin D supplementation, given as a vitamin D-fortified yogurt, and taking into consideration the age (65, 70, 80 years), the osteoporotic status (none, low BMD, PVF), and the amount of calcium (400 mg, 800 mg, 1200 mg) and vitamin D (200 IU, 400 IU, 600 IU) needed to reach the RNI. Whereas a previous study reported the impact of an increased dairy consumption on reducing the burden of osteoporosis in terms of health-outcomes and costs \[[@CR9]\], our research is the first to provide a full economic analysis, using a validated and widely accepted Monte Carlo microsimulation model \[[@CR13]\]. Another strength of our study relates to the sensitivity analyses assessing various supplementation regimens. However, if we rely on the average values of calcium intake in 25-OH hydroxyvitamin D serum concentrations reported in the literature for normal and osteoporotic elderly subjects, and the RNI for these nutrients \[[@CR2], [@CR3], [@CR5]--[@CR8], [@CR22], [@CR23], [@CR29], [@CR31]--[@CR34]\], we can reasonably assume that an intake of two portions of a fortified yogurt per day in the general population and one portion in the low BMD and PVF groups, on top of the existing dietary and pharmacological intakes, would be appropriate to ensure an optimal coverage of the calcium and vitamin D requirements. In this case, this strategy is cost-effective above 80 years in the general population but as early as 65 years old in patients at increased risk of osteoporotic fracture. For those individuals, from the general population, with a higher than average spontaneous intake in calcium and vitamin D, requesting only one portion of yogurt to reach the RNI, the strategy would be cost-effective from 70 years on while in those subjects with very low calcium/vitamin D intakes, who need three portions/day to compensate for their deficiency, cost-effectiveness will only be observed for all groups, above 80 years. Women with an increased risk of experiencing an osteoporotic fracture (low BMD or PVF) with an intermediate but less than average calcium and vitamin D intake, i.e., requesting two portions of yogurt per day to reach the RNI, would face a cost-effective strategy when aged 70 years and above.

Strength of this study includes the use of a rigorous systematic review on meta-analyses to assess the effects of calcium and vitamin D on fracture risk, which was conducted for our recent paper assessing the cost-effectiveness of pharmacological supplementation in calcium and vitamin D in elderly men and women with osteoporosis \[[@CR11]\]. Our estimates are also probably conservative for several reasons. First, different studies showed that calcium and vitamin D supplementation have other health benefit effects. So, studies suggested that calcium and vitamin D may reduce the risk for breast cancer mainly in premenopausal women \[[@CR35]\] and colon cancer in older women \[[@CR36]\]. A meta-analysis has also indicated that vitamin D may have a small beneficial effect on cardiovascular risk and mortality \[[@CR37], [@CR38]\]. Second, we used a conservative assumption about the efficacy of calcium and vitamin D on hip fracture. In the article of Boonen et al., high doses of calcium and vitamin D were associated with a slightly greater reduction of hip fracture risk \[[@CR22]\]. However, real-life studies, confirming that the administration of yogurt containing high doses of calcium and vitamin D provide the same extra-skeletal benefits than pharmacological administration of calcium and vitamin D would be of greatest interest.

Third, at every stage of life, adequate dietary intakes of key bone nutrients including calcium, vitamin D, and proteins contribute to muscle and bone health, thereby reducing the risk of falls, osteoporosis, and fractures in later life \[[@CR3]\]. Dairy products are rich in proteins \[[@CR33]\]. There is no clear-cut evidence that patients aged more than 65 years old have a deficit in protein intake similar to what is reported for calcium and vitamin D \[[@CR29]\]. However, it is possible that our analysis, based only on the beneficial effects of calcium and vitamin D on bone, without modeling the potential benefits of proteins underestimates the positive outcomes of dairy products intake.

Our study could have some potential limitations that could inform further economic evaluations. Like any health economics study, there are a large number of assumptions. This analysis of the cost-effectiveness of yogurt supplementation in older women is critically dependent on the evidence for efficacy of the intervention. It should be reminded that controversy exists in the literature related to anti-efficacy of calcium supplements with some recent meta-analyses of the effects of calcium on hip fracture in community-dwelling older people challenging the reduction in fracture risk \[[@CR39], [@CR40]\]. We did not incorporate adherence with dairy products which could potentially affect the cost-effectiveness of this strategy \[[@CR41]\]. Limited information about adherence to dairy products is currently available including the impact of non-adherence on treatment efficacy. It should be reminded that in Tang \[[@CR23]\] meta-analysis, compliance of \>80 % is necessary to achieve anti-fracture efficacy. We also made the assumption that by supplementing patients with variable doses of dairy calcium and vitamin D, based on their spontaneous intake of these nutrients (dietary or pharmacological), we would reach the target of at least 800 IU/day of vitamin D and 1 g/day of calcium, hence getting a similar clinical benefit on fracture risk. We acknowledge that this assumption has not been tested in clinical trials.

In conclusion, our study is the first economic analysis supporting the cost-effectiveness of dairy products, fortified with vitamin D, in the armamentarium against osteoporotic fractures. Dairy products have been repeatedly suggested as the most appropriate source of calcium and vitamin D supplementation in women at risk of osteoporotic fracture. Based on the average intake of these nutrients, reported in the literature, an additional daily intake of two portions in the general population and of one portion in women with low BMD or PVF, of a dairy product providing 400 mg of calcium and 200 IU of vitamin D, would be appropriate to meet the RNI for these nutriments. This strategy would be cost-effective from the age of 80 years in the general population and as early as 65 years old in women with low BMD or PVF. We provide different sensitivity analyses based on the age of the women, the presence or absence of osteoporosis, and the amount of calcium and vitamin D needed to meet the RNI.

In future research, adherence of women either in the general population or at high risk of osteoporosis to dairy products might be tested in long-term prospective trials. It would also be of interest to design willingness to pay studies to better understand to which extend individuals are ready to add dairy products to their diet to prevent osteoporosis.
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